The latest chapter in the long saga of Repros Therapeutics Inc.'s quest to get an estrogen blocker approved for secondary hypogonadism in overweight men gave investors cause for both optimism and concern, as the FDA's acceptance for filing of the new drug application (NDA) brought questions about the timing of an advisory committee meeting – and what U.S. gatekeepers might want next.